หน้าแรก
ค้นหา
Dr. Weber on Discontinuing Immunotherapy in Melanoma
No description available
แสดงข้อมูลเพิ่มเติม 1
Dr. Weber on Discontinuing Immunotherapy in Melanoma
Dr. Weber on Selecting Immunotherapy for Patients With Melanoma
Dr. Weber on Risk and Benefits With Immunotherapy Combos in Melanoma
Dr. Weber on Duration of Checkpoint Inhibitor Therapy in Melanoma
Dr. Weber on the Future of Checkpoint Inhibitors in Melanoma
Dr. Weber on FDA Approval of Pembrolizumab for Stage III Melanoma
Duration of Immunotherapy in Melanoma
Checkpoint inhibitor therapy for treating melanoma
Dr. Weber on Future Treatment Approaches for Patients With Melanoma
The Phenomenon of Immunotherapy in Melanoma
Long-Term Results for Immunotherapy in Melanoma
Jeffrey Weber, MD, PhD discusses the long term side effects with immunotherapies
Dr. Weber on the Toxicity Profile of Nivolumab Versus Ipilimumab for Melanoma
Metastatic Melanoma: The Immunotherapy Approach
Jeffrey Weber, MD, PhD, discusses the efficacy of checkpoint inhibitors and immunotherapy
Jeffrey Weber, MD, PhD explains the importance of administering ipilimumab with a PD-L1 inhibitor
Treatment Beyond Melanoma Progression
Dr. Jeffrey Weber on Ipilimumab for Melanoma
New Data for Melanoma Patients Who Progress After PD-1 Blockade
Managing Disease Progression in Metastatic Melanoma
